FDA approves new fluoroquinolone antibiotic, Baxdela
by Press Release from Outbreak News Today on (#2TECA)
Melinta Therapeutics announced Monday that the U.S. Food and Drug Administration (FDA) has approved Baxdelaa (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathogens, including MRSA (methicillin-resistant Staphylococcus aureus), and is ["]
The post FDA approves new fluoroquinolone antibiotic, Baxdela appeared first on Outbreak News Today.